Quick Facts: Promethazine HCl Syrup Therapeutic Domains

Area
Seasonal and perennial allergic rhinitis
Uncomplicated allergic skin manifestations (e.g., urticaria)
Prevention and control of nausea and vomiting
Treatment and prophylaxis of motion sickness
Sedation and relief of apprehension (preoperative, postoperative, and obstetric use)

---

Promethazine hydrochloride syrup is used in the clinical management of specific conditions where an antihistamine, antiemetic, or sedative effect is desired. The therapy is indicated for providing relief from symptoms associated with perennial and seasonal allergic rhinitis, including allergic conjunctivitis and vasomotor rhinitis.

The medication is also utilized for the symptomatic management of mild, uncomplicated allergic skin manifestations, such as urticaria (hives) and angioedema. When administered as adjunctive treatment, it assists in the amelioration of certain acute allergic reactions, including those related to blood or plasma products.

Promethazine also plays a role in the prevention and control of nausea and vomiting associated with specific causes, and for the active and prophylactic treatment of motion sickness. Additionally, it serves a purpose in sedation, providing relief of apprehension and producing light sleep in both children and adults, particularly in preoperative, postoperative, or obstetric settings. The precise usage and dosing should be determined by a qualified healthcare provider.

Eligibility for Promethazine HCl Syrup

The eligibility for Promethazine HCl Syrup is strictly defined by regulatory documents, distinguishing between populations for whom use is allowed, restricted, or contraindicated.

Eligibility Status	Population Entity
Absolute Contraindication	Pediatric patients less than 2 years of age; Individuals in a comatose state; Patients with known hypersensitivity to promethazine or other phenothiazines; Patients with lower respiratory tract symptoms (including asthma).
Conditional Use/Caution	Children 2 years of age and older; Older adult patients (geriatric); Patients with impaired liver function; Patients with cardiovascular disease; Patients with narrow-angle glaucoma or prostatic hypertrophy.

Promethazine HCl Syrup is contraindicated in children younger than two years of age due to the risk of potentially fatal respiratory depression, a warning emphasized across official regulatory labeling. Use in children two years and older requires strict caution and administration of the lowest effective dose. The medicine is also not recommended for use in lactating patients or during pregnancy, especially in the third trimester. For all adult patients, use requires caution if they have certain conditions that may be exacerbated by the drug’s properties, such as seizure disorders or bone-marrow depression.

Interactions with other medicines and products

Promethazine HCl Syrup interactions primarily involve additive effects with other agents and specific constraints on co-administration, as documented in regulatory information.

Pharmacodynamic Interactions

Co-administration with other Central Nervous System (CNS) depressants may increase, prolong, or intensify the sedative action of Promethazine HCl. These depressants include:

• Alcohol
• Sedatives and hypnotics (e.g., barbiturates)
• Narcotics and narcotic analgesics
• Tricyclic antidepressants and tranquilizers

When co-administered with promethazine, the dose of barbiturates is recommended to be reduced by at least one-half, and the dose of narcotics should be reduced by one-quarter to one-half.

Caution is required when using Promethazine HCl Syrup with other medications that possess anticholinergic properties due to the potential for additive effects. Additionally, drug interactions have been reported with Monoamine Oxidase Inhibitors (MAOI), potentially increasing the incidence of extrapyramidal effects.

Critical Co-administration Restrictions

Promethazine has the potential to reverse the vasopressor effect of epinephrine. Therefore, epinephrine must not be used to treat hypotension associated with promethazine overdose. Concomitant use with medications that may lower the seizure threshold, such as local anesthetics or certain narcotics, requires particular caution.

Population-Specific Notes

Co-administration with other respiratory depressants should be avoided in pediatric patients aged 2 years and older due to the heightened risk of respiratory depression.

Targeting the Histamine H1 System

Promethazine hydrochloride primarily functions as a competitive antagonist by blocking Histamine H1 receptors both peripherally and in the brain. This action suppresses signaling sequences initiated by histamine binding, which restricts the consequences of excessive mediator activity on blood vessel permeability and sensory nerve stimulation.

---

Modulating Central Emetic Pathways

The drug exhibits high lipophilicity, enabling rapid crossing of the Blood-Brain Barrier to target neural structures. It acts as an antagonist on both Muscarinic cholinergic and Dopamine D2 receptors within brain regions that control the vomiting reflex. This dual mechanism interrupts the afferent nerve signals from the balance centers and the Chemoreceptor Trigger Zone, results in the suppression of afferent emesis signaling.

---

Physiological Result: CNS Depression

The simultaneous antagonism of multiple central activating systems, particularly the H1 and Muscarinic pathways, results in generalized Central Nervous System (CNS) depression. This mechanism reduces the functional consequence of excitatory neurotransmission on brain function, producing a change in the dynamics of the arousal pathways and establishing the mechanism's influence on the central arousal systems.

Promethazine HCl Syrup is intended for administration via the oral route only, utilized strictly as an oral liquid. The product is manufactured in a standard concentration of 6.25 mg per 5 mL. Administration follows specific, indication-based dosing schedules.

For managing allergic symptoms, adults may use a single dose of 25 mg at bedtime or divided doses ranging from 6.25 mg to 12.5 mg taken before meals and at bedtime. For active treatment of nausea and vomiting, an initial 25 mg dose may be followed by 12.5 mg to 25 mg as needed, with doses repeated every 4 to 6 hours. Sedation, such as for nighttime or preoperative settings, typically involves a single dose of 25 mg to 50 mg.

Accurate administration requires the use of an accurate milliliter measuring device; household spoons are not considered sufficient for proper volume measurement. The dose may be taken with food, water, or milk to minimize gastric irritation. Use is strictly constrained by age: the syrup is contraindicated in children younger than 2 years of age, and weight-based dosing is employed for those 2 years and older. Furthermore, the dose for older adult patients should generally be reduced. A critical procedural rule stipulates that when Promethazine is co-administered with other Central Nervous System depressants, such as narcotics, the dose of the other depressant agent must be reduced by one-quarter to one-half. The frequency and dose must not be increased beyond the prescribed regimen.

Research Evidence / Overview of Studies for Promethazine HCl Syrup

Evidence for Symptomatic Relief of Allergic Conditions

Research examined conditions characterized by fluctuating or episodic allergic manifestations, such as seasonal and perennial allergic rhinitis and uncomplicated allergic skin conditions like urticaria (hives). Research in this area primarily consists of historical controlled clinical trials and regulatory summaries of the first-generation antihistamine drug class. These studies included populations of adults and children aged ge 2 years.

The research examined outcomes related to allergy symptom scores, specifically measuring symptom intensity for sneezing, nasal discharge, and the severity of skin rash or pruritus (itching). Research describes patterns where symptom scores were tracked during the short-term observation period. The evidence base contributes to understanding symptom patterns for this compound.

Evidence for Controlling Nausea and Vomiting

Research explored the use of the compound in conditions associated with acute or disruptive episodes, particularly for the prevention and control of nausea and vomiting in settings like postoperative care. The evidence base includes a mix of randomized controlled trials (RCTs), retrospective analyses, and comparative studies. Measured changes in outcomes related to functional imbalance, specifically the incidence and total frequency of vomiting or retching episodes, were reported during the study period.

Evidence for Sedation and Apprehension Relief

The research base includes studies conducted during periods of heightened symptom activity, such as the time before and after surgical or obstetric procedures, where it was evaluated for outcomes related to sedation and changes in apprehension. Study observations included measured data on sedation levels and patient-reported outcomes describing perceived discomfort. The main limitation is that the available evidence primarily derives from studies embedded within broader surgical or obstetric protocols.

---

What is Still Uncertain About the Research Landscape

Long-term outcomes are not well characterized, as the majority of studies focus on short-term symptom changes. Comparative evidence is lacking in modern RCTs for simple allergy management. The research base is characterized by identified research gaps, including where evidence remains heterogeneous and where regulatory reviews acknowledge limitations in the existing data.

Key Studies & References Promethazine - StatPearls

Common questions about Promethazine HCl Syrup (FAQ)

Q: What is Promethazine HCl Syrup typically used for?

Promethazine is an antihistamine used to treat symptoms of allergic conditions, motion sickness, and to prevent and control nausea and vomiting. It may also be used to produce light sedation or sleepiness in certain situations.

---

Q: Can I drive or operate machinery after taking this syrup?

Due to its potent sedative effects, Promethazine HCl Syrup may cause significant drowsiness, dizziness, and impaired coordination. Patients are strongly advised to avoid driving, operating heavy machinery, or participating in any activity requiring mental alertness after taking this medication.

---

Q: What is the most common side effect of Promethazine HCl Syrup?

The most common side effect reported with Promethazine is drowsiness or sedation. Other common side effects may include dizziness, blurred vision, and dry mouth. Patients should consult the official prescribing information for a comprehensive list of potential side effects.

How to Store and Dispose of Promethazine HCl Syrup

Promethazine HCl Syrup must be stored under specific environmental and packaging conditions to maintain product stability, as mandated by regulatory labeling.

---

Storage Requirements

Condition	Requirement
Temperature	Store at 20°C to 25°C (68°F to 77°F) (USP Controlled Room Temperature).
Protection	Must be protected from light and kept in a tightly closed, light-resistant container.
Child Safety	Keep out of the reach of children. The container must have a child-resistant closure.

---

Disposal Instructions

Expired or unused Promethazine HCl Syrup should be disposed of in accordance with local or state regulatory guidelines. It is recommended to utilize available drug take-back programs.